BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
August 20, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BL-new-logo.jpg
MODERNA, INC. (NASDAQ: MRNA) INVESTOR ALERT: Investors With Large Losses in Moderna, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
August 19, 2024 12:30 ET | Bernstein Liebhard LLP
MODERNA, INC. (NASDAQ: MRNA) INVESTOR ALERT: Investors With Large Losses in Moderna, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna and Sprinklr and Encourages Investors to Contact the Firm
August 18, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
August 16, 2024 17:36 ET | The Rosen Law Firm PA
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
BES_Mark.jpg
MODERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Moderna, Inc. and Encourages Investors to Contact the Firm
August 14, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Schall Firm Logo 2.jpg
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 14, 2024 12:50 ET | Schall Law
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
download.png
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024 09:02 ET | Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in...
BioNTech gibt erste
BioNTech gibt erste positive Ergebnisse aus laufender Phase-2-Studie mit mRNA-basiertem Immuntherapiekandidaten BNT111 bei fortgeschrittenem Hautkrebs bekannt
July 30, 2024 06:45 ET | BioNTech SE
Primärer Endpunkt in Phase-2-Studie erreicht, in der der mRNA-Immuntherapiekandidat BNT111 in Kombination mit dem PD-1-Checkpoint-Inhibitor Cemiplimab evaluiert wirdDaten zeigten eine statistisch...
BioNTech Announces P
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
July 30, 2024 06:45 ET | BioNTech SE
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
download.png
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
July 19, 2024 09:01 ET | Altamira Therapeutics Ltd
Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic...